Mesenchymal stem cells in primary Sjögren’s syndrome: Prospective and challenges

Weiqian Chen, Ye Yu, Jilin Ma, Nancy Olsen, Jin Lin

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Primary Sjögren’s syndrome (pSS) is a chronic systemic inflammatory autoimmune disease characterized by lymphocytic infiltrates in exocrine glands. Current approaches do not control harmful autoimmune attacks or prevent irreversible damage and have considerable side effects. Mesenchymal stem cells (MSCs) have been effective in the treatment of several autoimmune diseases. The objective of this review is to illustrate the potential therapeutic role of MSCs in pSS. We summarize the recent advances in what is known about their immunomodulatory function and therapeutic applications in pSS. MSC transfusion can suppress autoimmunity and restore salivary gland secretory function in mouse models and patients with pSS by inducing regulatory T cells, suppressing Th1, Th17, and T follicular helper cell responses. In addition, MSCs can differentiate into salivary epithelial cells, presenting an option as a suitable alternative treatment. We also discuss current bioengineering methods which improve functions of MSCs for pSS. However, there remain many challenges to overcome before their wide clinical application.

Original languageEnglish (US)
Article number4357865
JournalStem Cells International
Volume2018
DOIs
StatePublished - Jan 1 2018

Fingerprint

Mesenchymal Stromal Cells
Autoimmune Diseases
Exocrine Glands
Bioengineering
Regulatory T-Lymphocytes
Therapeutics
Helper-Inducer T-Lymphocytes
Salivary Glands
Autoimmunity
Epithelial Cells

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Cell Biology

Cite this

@article{6053fe22ea794eb4a87dd7de0b8aa916,
title = "Mesenchymal stem cells in primary Sj{\"o}gren’s syndrome: Prospective and challenges",
abstract = "Primary Sj{\"o}gren’s syndrome (pSS) is a chronic systemic inflammatory autoimmune disease characterized by lymphocytic infiltrates in exocrine glands. Current approaches do not control harmful autoimmune attacks or prevent irreversible damage and have considerable side effects. Mesenchymal stem cells (MSCs) have been effective in the treatment of several autoimmune diseases. The objective of this review is to illustrate the potential therapeutic role of MSCs in pSS. We summarize the recent advances in what is known about their immunomodulatory function and therapeutic applications in pSS. MSC transfusion can suppress autoimmunity and restore salivary gland secretory function in mouse models and patients with pSS by inducing regulatory T cells, suppressing Th1, Th17, and T follicular helper cell responses. In addition, MSCs can differentiate into salivary epithelial cells, presenting an option as a suitable alternative treatment. We also discuss current bioengineering methods which improve functions of MSCs for pSS. However, there remain many challenges to overcome before their wide clinical application.",
author = "Weiqian Chen and Ye Yu and Jilin Ma and Nancy Olsen and Jin Lin",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/4357865",
language = "English (US)",
volume = "2018",
journal = "Stem Cells International",
issn = "1687-9678",
publisher = "Hindawi Publishing Corporation",

}

Mesenchymal stem cells in primary Sjögren’s syndrome : Prospective and challenges. / Chen, Weiqian; Yu, Ye; Ma, Jilin; Olsen, Nancy; Lin, Jin.

In: Stem Cells International, Vol. 2018, 4357865, 01.01.2018.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Mesenchymal stem cells in primary Sjögren’s syndrome

T2 - Prospective and challenges

AU - Chen, Weiqian

AU - Yu, Ye

AU - Ma, Jilin

AU - Olsen, Nancy

AU - Lin, Jin

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Primary Sjögren’s syndrome (pSS) is a chronic systemic inflammatory autoimmune disease characterized by lymphocytic infiltrates in exocrine glands. Current approaches do not control harmful autoimmune attacks or prevent irreversible damage and have considerable side effects. Mesenchymal stem cells (MSCs) have been effective in the treatment of several autoimmune diseases. The objective of this review is to illustrate the potential therapeutic role of MSCs in pSS. We summarize the recent advances in what is known about their immunomodulatory function and therapeutic applications in pSS. MSC transfusion can suppress autoimmunity and restore salivary gland secretory function in mouse models and patients with pSS by inducing regulatory T cells, suppressing Th1, Th17, and T follicular helper cell responses. In addition, MSCs can differentiate into salivary epithelial cells, presenting an option as a suitable alternative treatment. We also discuss current bioengineering methods which improve functions of MSCs for pSS. However, there remain many challenges to overcome before their wide clinical application.

AB - Primary Sjögren’s syndrome (pSS) is a chronic systemic inflammatory autoimmune disease characterized by lymphocytic infiltrates in exocrine glands. Current approaches do not control harmful autoimmune attacks or prevent irreversible damage and have considerable side effects. Mesenchymal stem cells (MSCs) have been effective in the treatment of several autoimmune diseases. The objective of this review is to illustrate the potential therapeutic role of MSCs in pSS. We summarize the recent advances in what is known about their immunomodulatory function and therapeutic applications in pSS. MSC transfusion can suppress autoimmunity and restore salivary gland secretory function in mouse models and patients with pSS by inducing regulatory T cells, suppressing Th1, Th17, and T follicular helper cell responses. In addition, MSCs can differentiate into salivary epithelial cells, presenting an option as a suitable alternative treatment. We also discuss current bioengineering methods which improve functions of MSCs for pSS. However, there remain many challenges to overcome before their wide clinical application.

UR - http://www.scopus.com/inward/record.url?scp=85062892147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062892147&partnerID=8YFLogxK

U2 - 10.1155/2018/4357865

DO - 10.1155/2018/4357865

M3 - Review article

C2 - 30305818

AN - SCOPUS:85062892147

VL - 2018

JO - Stem Cells International

JF - Stem Cells International

SN - 1687-9678

M1 - 4357865

ER -